<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 09 Jul 2024 12:18:24 +0000</lastbuilddate>
<pubDate>Tue, 09 Jul 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>L-Wnk1 Deletion in Smooth Muscle Cells Causes Aortitis and Inflammatory Shift</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38979610/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION: Wnk1 is a key regulator of VSMC function. Wnk1 deletion promotes VSMC phenotype switch toward a pathogenic proinflammatory phenotype, orchestrating deleterious vascular remodeling and spontaneous severe aortitis in mice.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 9. doi: 10.1161/CIRCRESAHA.124.324366. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The long isoform of the Wnk1 (with-no-lysine [K] kinase 1) is a ubiquitous serine/threonine kinase, but its role in vascular smooth muscle cells (VSMCs) pathophysiology remains unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: AngII (angiotensin II) was infused in <i>Apoe</i><sup><i>-/-</i></sup> to induce experimental aortic aneurysm. Mice carrying an <i>Sm22-Cre</i> allele were cross-bred with mice carrying a floxed <i>Wnk1</i> allele to specifically investigate the functional role of Wnk1 in VSMCs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Single-cell RNA-sequencing of the aneurysmal abdominal aorta from AngII-infused <i>Apoe</i><sup><i>-/-</i></sup> mice revealed that VSMCs that did not express Wnk1 showed lower expression of contractile phenotype markers and increased inflammatory activity. Interestingly, WNK1 gene expression in VSMCs was decreased in human abdominal aortic aneurysm. <i>Wnk1</i>-deficient VSMCs lost their contractile function and exhibited a proinflammatory phenotype, characterized by the production of matrix metalloproteases, as well as cytokines and chemokines, which contributed to local accumulation of inflammatory macrophages, Ly6C<sup>hi</sup> monocytes, and γδ T cells. <i>Sm22Cre+Wnk1</i><sup><i>lox/lox</i></sup> mice spontaneously developed aortitis in the infrarenal abdominal aorta, which extended to the thoracic area over time without any negative effect on long-term survival. AngII infusion in <i>Sm22Cre+Wnk1</i><sup><i>lox/lox</i></sup> mice aggravated the aortic disease, with the formation of lethal abdominal aortic aneurysms. Pharmacological blockade of γδ T-cell recruitment using neutralizing anti-CXCL9 antibody treatment, or of monocyte/macrophage using Ki20227, a selective inhibitor of CSF1 receptor, attenuated aortitis. <i>Wnk1</i> deletion in VSMCs led to aortic wall remodeling with destruction of elastin layers, increased collagen content, and enhanced local TGF-β (transforming growth factor-beta) 1 expression. Finally, in vivo TGF-β blockade using neutralizing anti-TGF-β antibody promoted saccular aneurysm formation and aorta rupture in <i>Sm22 Cre+ Wnk1</i><sup><i>lox/lox</i></sup> mice but not in control animals.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: Wnk1 is a key regulator of VSMC function. <i>Wnk1</i> deletion promotes VSMC phenotype switch toward a pathogenic proinflammatory phenotype, orchestrating deleterious vascular remodeling and spontaneous severe aortitis in mice.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38979610/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38979610</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324366>10.1161/CIRCRESAHA.124.324366</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38979610</guid>
<pubDate>Tue, 09 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Helene Quelquejay</dc:creator>
<dc:creator>Rida Al-Rifai</dc:creator>
<dc:creator>Michele Silvestro</dc:creator>
<dc:creator>Marie Vandestienne</dc:creator>
<dc:creator>Irmine Ferreira</dc:creator>
<dc:creator>Tristan Mirault</dc:creator>
<dc:creator>Henrion Daniel</dc:creator>
<dc:creator>Xiaodan Zhong</dc:creator>
<dc:creator>Icia Santos-Zas</dc:creator>
<dc:creator>Guillaume Goudot</dc:creator>
<dc:creator>Paul Alayrac</dc:creator>
<dc:creator>Estelle Robidel</dc:creator>
<dc:creator>Gwennhael Autret</dc:creator>
<dc:creator>Daniel Balvay</dc:creator>
<dc:creator>Soraya Taleb</dc:creator>
<dc:creator>Alain Tedgui</dc:creator>
<dc:creator>Chantal M Boulanger</dc:creator>
<dc:creator>Alma Zernecke</dc:creator>
<dc:creator>Antoine-Emmanuel Saliba</dc:creator>
<dc:creator>Juliette Hadchouel</dc:creator>
<dc:creator>Bhama Ramkhelawon</dc:creator>
<dc:creator>Clement Cochain</dc:creator>
<dc:creator>Sonia Bergaya</dc:creator>
<dc:creator>Xavier Jeunemaitre</dc:creator>
<dc:creator>Hafid Ait-Oufella</dc:creator>
<dc:date>2024-07-09</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>L-Wnk1 Deletion in Smooth Muscle Cells Causes Aortitis and Inflammatory Shift</dc:title>
<dc:identifier>pmid:38979610</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324366</dc:identifier>
</item>
<item>
<title>Correction to: Nitrative Modification of Caveolin-3: A Novel Mechanism of Cardiac Insulin Resistance and a Potential Therapeutic Target against Ischemic Heart Failure in Prediabetic Animals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38976615/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 9;150(2):e63. doi: 10.1161/CIR.0000000000001270. Epub 2024 Jul 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38976615/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38976615</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001270>10.1161/CIR.0000000000001270</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38976615</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Nitrative Modification of Caveolin-3: A Novel Mechanism of Cardiac Insulin Resistance and a Potential Therapeutic Target against Ischemic Heart Failure in Prediabetic Animals</dc:title>
<dc:identifier>pmid:38976615</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001270</dc:identifier>
</item>
<item>
<title>Correction to: Jmjd4 Facilitates Pkm2 Degradation in Cardiomyocytes and Is Protective Against Dilated Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38976614/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 9;150(2):e64. doi: 10.1161/CIR.0000000000001268. Epub 2024 Jul 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38976614/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38976614</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001268>10.1161/CIR.0000000000001268</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38976614</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Jmjd4 Facilitates Pkm2 Degradation in Cardiomyocytes and Is Protective Against Dilated Cardiomyopathy</dc:title>
<dc:identifier>pmid:38976614</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001268</dc:identifier>
</item>
<item>
<title>Correction to: C1q/Tumor Necrosis Factor-Related Protein-9 Regulates the Fate of Implanted Mesenchymal Stem Cells and Mobilizes Their Protective Effects Against Ischemic Heart Injury via Multiple Novel Signaling Pathways</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38976613/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 9;150(2):e62. doi: 10.1161/CIR.0000000000001269. Epub 2024 Jul 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38976613/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38976613</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001269>10.1161/CIR.0000000000001269</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38976613</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: C1q/Tumor Necrosis Factor-Related Protein-9 Regulates the Fate of Implanted Mesenchymal Stem Cells and Mobilizes Their Protective Effects Against Ischemic Heart Injury via Multiple Novel Signaling Pathways</dc:title>
<dc:identifier>pmid:38976613</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001269</dc:identifier>
</item>
<item>
<title>Spexin Hormone Signaling and Atrial Fibrillation: The Knowns and Unknowns</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38976612/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 9;150(2):128-131. doi: 10.1161/CIRCULATIONAHA.124.070016. Epub 2024 Jul 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38976612/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38976612</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070016>10.1161/CIRCULATIONAHA.124.070016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38976612</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jordi Heijman</dc:creator>
<dc:creator>Dobromir Dobrev</dc:creator>
<dc:date>2024-07-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Spexin Hormone Signaling and Atrial Fibrillation: The Knowns and Unknowns</dc:title>
<dc:identifier>pmid:38976612</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070016</dc:identifier>
</item>
<item>
<title>Response by van Doorn et al to Letters Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38976611/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 9;150(2):e30-e32. doi: 10.1161/CIRCULATIONAHA.124.070172. Epub 2024 Jul 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38976611/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38976611</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070172>10.1161/CIRCULATIONAHA.124.070172</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38976611</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Sander van Doorn</dc:creator>
<dc:creator>Frans H Rutten</dc:creator>
<dc:creator>Geert-Jan Geersing</dc:creator>
<dc:date>2024-07-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by van Doorn et al to Letters Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial"</dc:title>
<dc:identifier>pmid:38976611</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070172</dc:identifier>
</item>
<item>
<title>Million Hearts Model Reduces Cardiovascular Events Without Increasing Care Costs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38976610/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 9;150(2):162-164. doi: 10.1161/CIRCULATIONAHA.123.067830. Epub 2024 Jul 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38976610/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38976610</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067830>10.1161/CIRCULATIONAHA.123.067830</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38976610</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Bridget M Kuehn</dc:creator>
<dc:date>2024-07-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Million Hearts Model Reduces Cardiovascular Events Without Increasing Care Costs</dc:title>
<dc:identifier>pmid:38976610</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067830</dc:identifier>
</item>
<item>
<title>Past, Present, and Future of CTA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38976609/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 9;150(2):87-90. doi: 10.1161/CIRCULATIONAHA.124.068325. Epub 2024 Jul 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38976609/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38976609</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068325>10.1161/CIRCULATIONAHA.124.068325</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38976609</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Suhny Abbara</dc:creator>
<dc:creator>Leslee J Shaw</dc:creator>
<dc:date>2024-07-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Past, Present, and Future of CTA</dc:title>
<dc:identifier>pmid:38976609</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068325</dc:identifier>
</item>
<item>
<title>Letter by Ko et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38976608/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 9;150(2):e25-e26. doi: 10.1161/CIRCULATIONAHA.123.067600. Epub 2024 Jul 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38976608/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38976608</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067600>10.1161/CIRCULATIONAHA.123.067600</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38976608</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Darae Ko</dc:creator>
<dc:creator>Dae Hyun Kim</dc:creator>
<dc:creator>Daniel E Singer</dc:creator>
<dc:date>2024-07-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Ko et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial"</dc:title>
<dc:identifier>pmid:38976608</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067600</dc:identifier>
</item>
<item>
<title>Ischemia Severity, Coronary Artery Disease Extent, and Exercise Capacity in ISCHEMIA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38976607/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 9;150(2):165-167. doi: 10.1161/CIRCULATIONAHA.123.066980. Epub 2024 Jul 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38976607/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38976607</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066980>10.1161/CIRCULATIONAHA.123.066980</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38976607</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jerome L Fleg</dc:creator>
<dc:creator>Zhen Huang</dc:creator>
<dc:creator>Harmony R Reynolds</dc:creator>
<dc:creator>Leslee J Shaw</dc:creator>
<dc:creator>Bernard R Chaitman</dc:creator>
<dc:creator>Sean M O'Brien</dc:creator>
<dc:creator>Leonid Berstein</dc:creator>
<dc:creator>Jesus Peteiro</dc:creator>
<dc:creator>Paola E P Smanio</dc:creator>
<dc:creator>Gurpreet S Wander</dc:creator>
<dc:creator>Jeffrey S Berger</dc:creator>
<dc:creator>Daniel S Berman</dc:creator>
<dc:creator>Michael H Picard</dc:creator>
<dc:creator>Raymond Y Kwong</dc:creator>
<dc:creator>James K Min</dc:creator>
<dc:creator>Lawrence M Phillips</dc:creator>
<dc:creator>Sripal Bangalore</dc:creator>
<dc:creator>David J Maron</dc:creator>
<dc:creator>Judith S Hochman</dc:creator>
<dc:creator>ISCHEMIA Research Group</dc:creator>
<dc:date>2024-07-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Ischemia Severity, Coronary Artery Disease Extent, and Exercise Capacity in ISCHEMIA</dc:title>
<dc:identifier>pmid:38976607</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066980</dc:identifier>
</item>
<item>
<title>Letter by Suwa et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38976606/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 9;150(2):e27. doi: 10.1161/CIRCULATIONAHA.124.069068. Epub 2024 Jul 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38976606/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38976606</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069068>10.1161/CIRCULATIONAHA.124.069068</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38976606</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Michihiro Suwa</dc:creator>
<dc:creator>Isao Morii</dc:creator>
<dc:creator>Masaya Kino</dc:creator>
<dc:date>2024-07-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Suwa et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial"</dc:title>
<dc:identifier>pmid:38976606</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069068</dc:identifier>
</item>
<item>
<title>Letter by Millis et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38976605/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 9;150(2):e23-e24. doi: 10.1161/CIRCULATIONAHA.123.067571. Epub 2024 Jul 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38976605/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38976605</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067571>10.1161/CIRCULATIONAHA.123.067571</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38976605</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Christopher E Millis</dc:creator>
<dc:creator>Denise F Feradov</dc:creator>
<dc:creator>Xavier E Prida</dc:creator>
<dc:date>2024-07-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Millis et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial"</dc:title>
<dc:identifier>pmid:38976605</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067571</dc:identifier>
</item>
<item>
<title>Letter by Lin Regarding Article, "Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38976604/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 9;150(2):e21-e22. doi: 10.1161/CIRCULATIONAHA.123.067391. Epub 2024 Jul 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38976604/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38976604</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067391>10.1161/CIRCULATIONAHA.123.067391</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38976604</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Yongjian Lin</dc:creator>
<dc:date>2024-07-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Lin Regarding Article, "Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial"</dc:title>
<dc:identifier>pmid:38976604</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067391</dc:identifier>
</item>
<item>
<title>Letter by Kohsaka et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38976603/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 9;150(2):e28-e29. doi: 10.1161/CIRCULATIONAHA.124.069363. Epub 2024 Jul 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38976603/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38976603</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069363>10.1161/CIRCULATIONAHA.124.069363</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38976603</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Shun Kohsaka</dc:creator>
<dc:creator>Shiori Nishimura</dc:creator>
<dc:creator>Hiraku Kumamaru</dc:creator>
<dc:date>2024-07-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Kohsaka et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial"</dc:title>
<dc:identifier>pmid:38976603</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069363</dc:identifier>
</item>
<item>
<title>Sex differences in treatment of familial hypercholesterolaemia: a meta-analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38976372/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Females with FH were less likely to be treated intensively and to reach guideline-recommended LDL-C targets. This sex bias represents a surmountable barrier to clinical care.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 8:ehae417. doi: 10.1093/eurheartj/ehae417. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Familial hypercholesterolaemia (FH) is a highly prevalent monogenic disorder characterized by elevated LDL cholesterol (LDL-C) levels and premature atherosclerotic cardiovascular disease. Sex disparities in diagnosis, lipid-lowering therapy, and achieved lipid levels have emerged worldwide, resulting in barriers to care in FH. A systematic review was performed to investigate sex-related disparities in treatment, response, and lipid target achievement in FH (PROSPERO, CRD42022353297).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: MEDLINE, Embase, The Cochrane library, PubMed, Scopus, PsycInfo, and grey literature databases were searched from inception to 26 April 2023. Records were eligible if they described sex differences in the treatment of adults with FH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 4432 publications reviewed, 133 met our eligibility criteria. In 16 interventional clinical trials (eight randomized and eight non-randomized; 1840 participants, 49.4% females), there were no differences between males and females in response to fixed doses of lipid-lowering therapy, suggesting that sex was not a determinant of response. Meta-analysis of 25 real-world observational studies (129 441 participants, 53.4% females) found that females were less likely to be on lipid-lowering therapy compared with males (odds ratio .74, 95% confidence interval .66-.85). Importantly, females were less likely to reach an LDL-C &lt; 2.5 mmol/L (odds ratio .85, 95% confidence interval .74-.97). Similarly, treated LDL-C levels were higher in females. Despite this, male sex was associated with a two-fold greater relative risk of major adverse cardiovascular events including myocardial infarction, atherosclerotic cardiovascular disease, and cardiovascular mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Females with FH were less likely to be treated intensively and to reach guideline-recommended LDL-C targets. This sex bias represents a surmountable barrier to clinical care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38976372/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38976372</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae417>10.1093/eurheartj/ehae417</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38976372</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Iulia Iatan</dc:creator>
<dc:creator>Leo E Akioyamen</dc:creator>
<dc:creator>Isabelle Ruel</dc:creator>
<dc:creator>Amanda Guerin</dc:creator>
<dc:creator>Lindsay Hales</dc:creator>
<dc:creator>Thais Coutinho</dc:creator>
<dc:creator>Liam R Brunham</dc:creator>
<dc:creator>Jacques Genest</dc:creator>
<dc:date>2024-07-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sex differences in treatment of familial hypercholesterolaemia: a meta-analysis</dc:title>
<dc:identifier>pmid:38976372</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae417</dc:identifier>
</item>
<item>
<title>Artificial intelligence-enhanced patient evaluation: bridging art and science</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38976371/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>The advent of digital health and artificial intelligence (AI) has promised to revolutionize clinical care, but real-world patient evaluation has yet to witness transformative changes. As history taking and physical examination continue to rely on long-established practices, a growing pipeline of AI-enhanced digital tools may soon augment the traditional clinical encounter into a data-driven process. This article presents an evidence-backed vision of how promising AI applications may enhance...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 8:ehae415. doi: 10.1093/eurheartj/ehae415. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The advent of digital health and artificial intelligence (AI) has promised to revolutionize clinical care, but real-world patient evaluation has yet to witness transformative changes. As history taking and physical examination continue to rely on long-established practices, a growing pipeline of AI-enhanced digital tools may soon augment the traditional clinical encounter into a data-driven process. This article presents an evidence-backed vision of how promising AI applications may enhance traditional practices, streamlining tedious tasks while elevating diverse data sources, including AI-enabled stethoscopes, cameras, and wearable sensors, to platforms for personalized medicine and efficient care delivery. Through the lens of traditional patient evaluation, we illustrate how digital technologies may soon be interwoven into routine clinical workflows, introducing a novel paradigm of longitudinal monitoring. Finally, we provide a skeptic's view on the practical, ethical, and regulatory challenges that limit the uptake of such technologies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38976371/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38976371</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae415>10.1093/eurheartj/ehae415</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38976371</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Evangelos K Oikonomou</dc:creator>
<dc:creator>Rohan Khera</dc:creator>
<dc:date>2024-07-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence-enhanced patient evaluation: bridging art and science</dc:title>
<dc:identifier>pmid:38976371</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae415</dc:identifier>
</item>
<item>
<title>Lumican promotes calcific aortic valve disease through H3 histone lactylation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38976370/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The study presents novel findings, being the first to establish the involvement of lumican in mediating H3 histone lactylation, thus facilitating the development of aortic valve calcification. Consequently, lumican would be a promising therapeutic target for intervention in the treatment of CAVD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 8:ehae407. doi: 10.1093/eurheartj/ehae407. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Valve interstitial cells (VICs) undergo a transition to intermediate state cells before ultimately transforming into the osteogenic cell population, which is a pivotal cellular process in calcific aortic valve disease (CAVD). Herein, this study successfully delineated the stages of VIC osteogenic transformation and elucidated a novel key regulatory role of lumican (LUM) in this process.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Single-cell RNA-sequencing (scRNA-seq) from nine human aortic valves was used to characterize the pathological switch process and identify key regulatory factors. The in vitro, ex vivo, in vivo, and double knockout mice were constructed to further unravel the calcification-promoting effect of LUM. Moreover, the multi-omic approaches were employed to analyse the molecular mechanism of LUM in CAVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: ScRNA-seq successfully delineated the process of VIC pathological transformation and highlighted the significance of LUM as a novel molecule in this process. The pro-calcification role of LUM is confirmed on the in vitro, ex vivo, in vivo level, and ApoE-/-//LUM-/- double knockout mice. The LUM induces osteogenesis in VICs via activation of inflammatory pathways and augmentation of cellular glycolysis, resulting in the accumulation of lactate. Subsequent investigation has unveiled a novel LUM driving histone modification, lactylation, which plays a role in facilitating valve calcification. More importantly, this study has identified two specific sites of histone lactylation, namely, H3K14la and H3K9la, which have been found to facilitate the process of calcification. The confirmation of these modification sites' association with the expression of calcific genes Runx2 and BMP2 has been achieved through ChIP-PCR analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The study presents novel findings, being the first to establish the involvement of lumican in mediating H3 histone lactylation, thus facilitating the development of aortic valve calcification. Consequently, lumican would be a promising therapeutic target for intervention in the treatment of CAVD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38976370/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38976370</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae407>10.1093/eurheartj/ehae407</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38976370</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Yuming Huang</dc:creator>
<dc:creator>Chunli Wang</dc:creator>
<dc:creator>Tingwen Zhou</dc:creator>
<dc:creator>Fei Xie</dc:creator>
<dc:creator>Zongtao Liu</dc:creator>
<dc:creator>Haiying Xu</dc:creator>
<dc:creator>Ming Liu</dc:creator>
<dc:creator>Shunshun Wang</dc:creator>
<dc:creator>Lanqing Li</dc:creator>
<dc:creator>Qingjia Chi</dc:creator>
<dc:creator>Jiawei Shi</dc:creator>
<dc:creator>Nianguo Dong</dc:creator>
<dc:creator>Kang Xu</dc:creator>
<dc:date>2024-07-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Lumican promotes calcific aortic valve disease through H3 histone lactylation</dc:title>
<dc:identifier>pmid:38976370</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae407</dc:identifier>
</item>
<item>
<title>Atrioventricular Synchrony Delivered by a Dual-Chamber Leadless Pacemaker System</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38973458/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This dual-chamber leadless pacemaker system demonstrated AV synchrony in 98% of evaluable beats at 3 months after implantation. AV synchrony was maintained across postures/activities and remained robust for heart rates >;100 bpm.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 8. doi: 10.1161/CIRCULATIONAHA.124.069006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: A dual-chamber leadless pacemaker system has been designed for AV synchronous pacing using wireless, beat-to-beat, implant-to-implant (i2i) communication between distinct atrial and ventricular leadless pacemakers. The AV synchrony achieved across various ambulatory scenarios has yet to be systematically evaluated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A prospective, single-arm, unblinded, multicenter, international clinical trial of the leadless pacemaker system was conducted in patients with a conventional dual-chamber pacing indication enrolled from February 2022 to March 2023. Leadless pacemaker systems were implanted, and 12-lead Holter electrocardiographic recordings were collected 3 months after implantation over various postures/activities: sitting, supine, left lateral recumbent, right lateral recumbent, standing, normal walk, and fast walk. An independent Holter core laboratory performed a manual adjudication of the percent of AV synchronous beats using the standard 300-millisecond PR interval limit. Atrium-to-ventricle and ventricle-to-atrium i2i communication success rates were also assessed. Post hoc summary statistics describing the relationships between AV synchrony and i2i success, posture/activity, implantation indication, AV event, and heart rate were calculated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the evaluable population (n=384 of 464 enrolled [83%]; 61% male; age, 70 years; weight, 82 kg; 60% ejection fraction; 95% of beats evaluable), the mean AV synchrony of 98% of beats observed across all postures using the standard 300-millisecond limit was greater than both atrium-to-ventricle i2i (94%) and ventricle-to-atrium i2i (94%; <i>P</i>&lt;0.001), exceeding both i2i values in 95% of patients. AV synchrony was achieved in >;95% of evaluable beats across all postures/activities, implantation indications, AV paced/sensed event combinations, and heart rate ranges (including >;100 bpm).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This dual-chamber leadless pacemaker system demonstrated AV synchrony in 98% of evaluable beats at 3 months after implantation. AV synchrony was maintained across postures/activities and remained robust for heart rates >;100 bpm.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38973458/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38973458</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069006>10.1161/CIRCULATIONAHA.124.069006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38973458</guid>
<pubDate>Mon, 08 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>James E Ip</dc:creator>
<dc:creator>Mayer Rashtian</dc:creator>
<dc:creator>Derek V Exner</dc:creator>
<dc:creator>Vivek Y Reddy</dc:creator>
<dc:creator>Rahul Doshi</dc:creator>
<dc:creator>Nima Badie</dc:creator>
<dc:creator>Jordan R Nevo</dc:creator>
<dc:creator>Aditya Goil</dc:creator>
<dc:creator>Pascal Defaye</dc:creator>
<dc:creator>Robert Canby</dc:creator>
<dc:creator>Maria Grazia Bongiorni</dc:creator>
<dc:creator>Morio Shoda</dc:creator>
<dc:creator>Gerhard Hindricks</dc:creator>
<dc:creator>Reinoud E Knops</dc:creator>
<dc:date>2024-07-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Atrioventricular Synchrony Delivered by a Dual-Chamber Leadless Pacemaker System</dc:title>
<dc:identifier>pmid:38973458</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069006</dc:identifier>
</item>
<item>
<title>Guideline-recommended medical therapy for de novo heart failure with reduced ejection fraction: be patient waiting for reverse remodelling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38973022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 8:ehae400. doi: 10.1093/eurheartj/ehae400. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38973022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38973022</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae400>10.1093/eurheartj/ehae400</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38973022</guid>
<pubDate>Sun, 07 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Josip Andelo Borovac</dc:creator>
<dc:date>2024-07-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Guideline-recommended medical therapy for de novo heart failure with reduced ejection fraction: be patient waiting for reverse remodelling</dc:title>
<dc:identifier>pmid:38973022</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae400</dc:identifier>
</item>
<item>
<title>Implantable loop recorders in Brugada syndrome: symptoms and arrhythmia characterization</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38973021/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 8:ehae428. doi: 10.1093/eurheartj/ehae428. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38973021/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38973021</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae428>10.1093/eurheartj/ehae428</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38973021</guid>
<pubDate>Sun, 07 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Giulio Conte</dc:creator>
<dc:creator>Marco Bergonti</dc:creator>
<dc:date>2024-07-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Implantable loop recorders in Brugada syndrome: symptoms and arrhythmia characterization</dc:title>
<dc:identifier>pmid:38973021</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae428</dc:identifier>
</item>
<item>
<title>Implantable loop recorders in patients with Brugada syndrome: the importance of a correct patient stratification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38973020/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240709081823&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 8:ehae393. doi: 10.1093/eurheartj/ehae393. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38973020/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240709081823&v=2.18.0.post9+e462414">38973020</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae393>10.1093/eurheartj/ehae393</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38973020</guid>
<pubDate>Sun, 07 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregory Dendramis</dc:creator>
<dc:date>2024-07-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Implantable loop recorders in patients with Brugada syndrome: the importance of a correct patient stratification</dc:title>
<dc:identifier>pmid:38973020</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae393</dc:identifier>
</item>





























</channel>
</rss>